PLEK2: A Potential Drug Target and Biomarker (G26499)

Target Name: PLEK2

NCBI ID: G26499

PLEK2: A Potential Drug Target and Biomarker

Pleckstrin-2 (PLEK2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidney. It is a member of the PIK/AIDA family, which includes proteins that are involved in the regulation of intracellular signaling pathways. PLEK2 has been shown to play a role in a variety of physiological processes, including cell signaling, inflammation, and fibrosis. As a result, PLEK2 has potential as a drug target and biomarker.

The PIK/AIDA family of proteins is characterized by the presence of a nucleotide-binding oligomerization domain (NBD), which is a structural motif that is involved in the regulation of protein-protein interactions. PLEK2 also contains a catalytic domain, which is responsible for the catalytic activity of the protein. The catalytic domain of PLEK2 contains a single catalytic subunit, which is responsible for the catalytic activity of the protein.

PLEK2 has been shown to play a role in a variety of physiological processes. For example, PLEK2 has been shown to be involved in the regulation of cell signaling pathways, including the regulation of cell adhesion, migration, and the formation of tight junctions. PLEK2 has also been shown to be involved in the regulation of inflammation, including the regulation of immune cell function and the modulation of inflammation.

In addition to its role in physiological processes, PLEK2 has also been shown to be a potential drug target. The PIK/AIDA family of proteins has been shown to be involved in the regulation of a variety of cellular processes, including cell signaling, inflammation, and fibrosis. As a result, PLEK2 has potential as a drug target for a variety of diseases, including cancer, neurodegenerative diseases, and fibrosis.

One potential mechanism by which PLEK2 could be targeted as a drug is its role in the regulation of cell signaling pathways. PLEK2 has been shown to play a role in the regulation of cell adhesion, migration, and the formation of tight junctions, and these processes are often disrupted in diseases such as cancer and neurodegenerative diseases. As a result, targeting PLEK2 with drugs that can modulate its function in these pathways could potentially lead to therapeutic benefits.

Another potential mechanism by which PLEK2 could be targeted as a drug is its role in the regulation of inflammation. PLEK2 has been shown to play a role in the regulation of immune cell function and the modulation of inflammation. As a result, targeting PLEK2 with drugs that can modulate its function in these pathways could potentially lead to therapeutic benefits in diseases such as cancer and autoimmune disorders.

In addition to its potential as a drug target, PLEK2 has also been shown to be a potential biomarker. The PIK/AIDA family of proteins is characterized by the presence of a nucleotide-binding oligomerization domain (NBD), which is a structural motif that is involved in the regulation of protein-protein interactions. PLEK2 contains a NBD, which could be used as a potential biomarker for the disease.

One potential approach to using PLEK2 as a biomarker is to use techniques such as affinity purification to selectively capture the NBD-containing fractions of PLEK2 and then use mass spectrometry to identify and quantify the NBD-containing fractions. This approach could be used to determine the levels of PLEK2 NBD in a variety of biological samples, including patient tissues, fluids, and biological fluids.

In conclusion, PLEK2 is a protein that is expressed in various tissues throughout the body and has potential as a drug target and biomarker. The PIK/AIDA family of proteins, including PLEK2, is characterized by the presence of a nucleotide-binding oligomerization domain (

Protein Name: Pleckstrin 2

Functions: May help orchestrate cytoskeletal arrangement. Contribute to lamellipodia formation

More Common Targets